エピレプシ の 大人 の ため の 抗発作 薬: レビュー
Andres M Kanner1, Manuel Melo Bicchi1
1Comprehensive Epilepsy Center and Epilepsy Division, Department of Neurology, University of Miami, Miller School of Medicine, Miami, Florida.
JAMA
|April 5, 2022
まとめ
の治療は,発作を制御し,怪我を防ぐことを目的としています. 抗発作薬 (ASD) を選択する際には,発作の種類,患者因子,潜在的な副作用を慎重に考慮する必要があります.
科学分野:
- 神経学
- 薬理学について
- エピレプト学
背景:
- は全世界で6500万人に感染し 怪我や死亡の危険性があります
- 抗発作薬 (ASD) の副作用を最小限に抑えながら,発作を排除することが有効な治療である.
- 発作の診断には 発作を焦点発作または一般発作として分類することが含まれます
研究 の 目的:
- 適切な抗発作薬 (ASD) を選択するための原則を概説する.
- エピレプシーの管理のための個別化された治療戦略を強調する.
- ASDの選択において併発症や薬物相互作用を考慮する重要性を強調する.
主な方法:
- 集中発作と一般発作に対するFDAの承認を受けた抗発作薬のレビュー.
- 発作の種類,症候群,患者の人口統計,併発症を含むASD選択に影響を与える要因の分析.
- 骨の健康や心血管疾患への影響など,薬物間の相互作用や潜在的な有害作用の検討
主要な成果:
- 約60~70%の患者は,現在のASDで発作がなくなる.
- 25~50%の患者は同時に起こる神経学的,精神的,または認知的障害を経験します.
- オックスカルバゼピンやラモトリジンなどの特定のASDは,焦点性の第一線治療薬であり,他のものは,一般性の個々の患者プロファイルに基づいて選択されます.
結論:
- 最適なエピレプシー治療には,発作の種類,エピレプシー症候群,患者の特徴,および併発症に基づいて個別化されたASD選択が必要です.
- ASDを慎重に選択することで 負傷,死亡,薬の副作用のリスクを軽減できます
- 併発性疾患と潜在的な薬物相互作用の管理は,包括的な治療に不可欠です.
さらに関連する動画
06:45Generation and On-Demand Initiation of Acute Ictal Activity in Rodent and Human Tissue
Published on: January 19, 2019
9.1K
10:23Equipment Setup and Artifact Removal for Simultaneous Electroencephalogram and Functional Magnetic Resonance Imaging for Clinical Review in Epilepsy
Published on: June 23, 2023
2.2K
関連する概念動画
01:08Antiepileptic Drugs: Sodium Channel Blockers
1.0K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
1.0K
01:24Epilepsy and Seizures: Overview
315
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
315
01:20Antiepileptic Drugs: Potassium Channel Activators
307
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
307
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
484
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
484
01:17Antiepileptic Drugs: Calcium Channel Blockers
695
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
695
01:14Antiepileptic Drugs: Glutamate Antagonists
546
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
546